Jonathan Hepple
Director/Miembro de la Junta en Nucleome Therapeutics Ltd. .
Perfil
Jonathan Hepple is currently a Non-Executive Director at MISSION Therapeutics Ltd., Carrick Therapeutics Ltd., Nucleome Therapeutics Ltd., Rosetta Capital Ltd., and Oxford Science Enterprises PLC.
He previously held positions as a Director at GlycoMimetics, Inc., ProCertus BioPharm, Inc., Aprea Therapeutics AB, NovImmune SA, Axelar AB, Covagen AG, Opsona Therapeutics Ltd., and Tranzyme Pharma, Inc. (Canada).
He was also a Director at ClanoTech AB from 2013 to 2020 and an Independent Director at Aprea Therapeutics, Inc. from 2015 to 2020.
Additionally, he worked as a Partner at Kernel Management Partners Ltd.
Dr. Hepple obtained his undergraduate degree from the University of Oxford in 1992 and his doctorate degree from the University of Cambridge in 1997.
Cargos activos de Jonathan Hepple
Empresas | Cargo | Inicio |
---|---|---|
Rosetta Capital Ltd.
Rosetta Capital Ltd. Investment ManagersFinance Rosetta Capital Ltd (Rosetta Capital) is a venture capital firm is founded in 2001 by Jeremy Curnock Cook, Michael Forer and Jonathan Hepple. The firm is headquartered in London. | Inversor de Capital Privado | 01/01/2001 |
MISSION Therapeutics Ltd.
MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | Director/Miembro de la Junta | 24/03/2021 |
Nucleome Therapeutics Ltd.
Nucleome Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Nucleome Therapeutics Ltd. develops small molecular drugs for autoimmune diseases. The company was founded by Danuta Mariola Jeziorska, James Raymond Hughes and James Davies and is headquartered in Oxford, the United Kingdom. | Director/Miembro de la Junta | 25/05/2021 |
Carrick Therapeutics Ltd.
Carrick Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Carrick Therapeutics Ltd. manufactures cancer therapeutics. The company is headquartered in Dublin, Ireland. | Director/Miembro de la Junta | - |
Oxford Science Enterprises PLC
Oxford Science Enterprises PLC Investment ManagersFinance Oxford Science Enterprises PLC (Oxford Science Enterprises) is a venture capital firm founded in 2015. The firm is headquartered in Oxford, United Kingdom. | Consultor / Asesor | 01/07/2020 |
Antiguos cargos conocidos de Jonathan Hepple.
Empresas | Cargo | Fin |
---|---|---|
APREA THERAPEUTICS, INC. | Director/Miembro de la Junta | 16/09/2020 |
ClanoTech AB
ClanoTech AB Pharmaceuticals: MajorHealth Technology ClanoTech AB is a holding company that develops drugs for the treatment of cancer and macular degeneration. Its lead candidate is an inhibitor of the alpha5beta1-integrin receptor which is present in fibroblast and on vascular endothelial cells. Its Alpha5beta1-integrin is strongly up-regulated in fibroblast when switching to the fibrotic state and in scars after glaucoma surgery. Its strategy spans from therapeutic areas with high commercial potential as wet Age Regulated Macular Degeneration to ophthalmology niche indications with orphan drug opportunity such as developing advent in glaucoma surgery techniques. The company was founded by Yihai Cao in 2006 and is headquartered in Solna, Sweden. | Director/Miembro de la Junta | 01/04/2020 |
Tranzyme Pharma, Inc. (Canada) | Director/Miembro de la Junta | - |
GLYCOMIMETICS, INC. | Director/Miembro de la Junta | - |
░░░░░░░░ ░░░░░░░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░ ░░░░░ | - |
Formación de Jonathan Hepple.
University of Oxford | Undergraduate Degree |
University of Cambridge | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
GLYCOMIMETICS, INC. | Health Technology |
APREA THERAPEUTICS, INC. | Health Technology |
Empresas privadas | 15 |
---|---|
Rosetta Capital Ltd.
Rosetta Capital Ltd. Investment ManagersFinance Rosetta Capital Ltd (Rosetta Capital) is a venture capital firm is founded in 2001 by Jeremy Curnock Cook, Michael Forer and Jonathan Hepple. The firm is headquartered in London. | Finance |
Kernel Management Partners Ltd.
Kernel Management Partners Ltd. Investment ManagersFinance Kernel Management Partners Ltd. (Kernel Capital) is a venture capital firm founded in 1999 by Niall Olden. The firm is headquartered in Cork, Ireland. | Finance |
ProCertus BioPharm, Inc.
ProCertus BioPharm, Inc. Pharmaceuticals: MajorHealth Technology ProCertus BioPharm, Inc. operates as an oncology-based pharmaceutical company. Its product includes DermX, ProDermaCel, and OralX, proprietary pharmaceuticals which are designed to reduce or eliminate the side effects associated with cancer therapy. ProDermaCel will protect cancer patients from chemotherapy- and radiotherapy-induced alopecia (hair loss), DermX will prevent radiotherapy-induced dermatitis (skin burn), and OralX will protect against chemotherapy- and radiotherapy-induced oral mucositis. The company was founded by William E. Fahl and in 1997 and is headquartered in Madison, WI. | Health Technology |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Health Technology |
Novimmune SA
Novimmune SA Medical/Nursing ServicesHealth Services Novimmune SA discovers and develops antibody-based drugs targeted for the treatment of inflammatory diseases, immune-related disorders and cancer. The company was founded by Bernard Mach in 1998 and is headquartered in Plan-les-Ouates, Switzerland. | Health Services |
Axelar AB
Axelar AB BiotechnologyHealth Technology Axelar AB operates as a biotechnology company. It aims to develop novel efficacious anti-cancer treatments. The company was founded by Erik Gustav Magnus Axelson and Lars Olov Larsson in 2003 and is headquartered in Solna, Sweden. | Health Technology |
Covagen AG
Covagen AG BiotechnologyHealth Technology Covagen AG engages in the research in as well as development, production, and distribution of pharmaceutical and diagnostic products and technologies. The company was founded by Julian Bertschinger and Dragan Grabulovski in 2007 and is headquartered in Zug, Switzerland. | Health Technology |
Opsona Therapeutics Ltd.
Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland. | Health Technology |
Tranzyme Pharma, Inc. (Canada) | |
ClanoTech AB
ClanoTech AB Pharmaceuticals: MajorHealth Technology ClanoTech AB is a holding company that develops drugs for the treatment of cancer and macular degeneration. Its lead candidate is an inhibitor of the alpha5beta1-integrin receptor which is present in fibroblast and on vascular endothelial cells. Its Alpha5beta1-integrin is strongly up-regulated in fibroblast when switching to the fibrotic state and in scars after glaucoma surgery. Its strategy spans from therapeutic areas with high commercial potential as wet Age Regulated Macular Degeneration to ophthalmology niche indications with orphan drug opportunity such as developing advent in glaucoma surgery techniques. The company was founded by Yihai Cao in 2006 and is headquartered in Solna, Sweden. | Health Technology |
MISSION Therapeutics Ltd.
MISSION Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Carrick Therapeutics Ltd.
Carrick Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Carrick Therapeutics Ltd. manufactures cancer therapeutics. The company is headquartered in Dublin, Ireland. | Health Technology |
Catalyst Biosciences, Inc.
Catalyst Biosciences, Inc. BiotechnologyHealth Technology Catalyst Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of novel medicines to address serious medical conditions. The company was founded on March 7, 1997 and is headquartered in South San Francisco, CA. | Health Technology |
Oxford Science Enterprises PLC
Oxford Science Enterprises PLC Investment ManagersFinance Oxford Science Enterprises PLC (Oxford Science Enterprises) is a venture capital firm founded in 2015. The firm is headquartered in Oxford, United Kingdom. | Finance |
Nucleome Therapeutics Ltd.
Nucleome Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Nucleome Therapeutics Ltd. develops small molecular drugs for autoimmune diseases. The company was founded by Danuta Mariola Jeziorska, James Raymond Hughes and James Davies and is headquartered in Oxford, the United Kingdom. | Health Technology |
- Bolsa de valores
- Insiders
- Jonathan Hepple